WallStSmart
BOLT

Bolt Biotherapeutics

NASDAQ: BOLT · HEALTHCARE · BIOTECHNOLOGY

$4.87
+2.21% today

Updated 2026-04-30

Market cap
$9.28M
P/E ratio
—
P/S ratio
1.21x
EPS (TTM)
$-17.85
Dividend yield
—
52W range
$4 – $9
Volume
0.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Bolt Biotherapeutics (BOLT) Financial statements

SEC filings — annual and quarterly data.

Income statementBalance sheetCash flowProfitability

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$215000.00$231000.00$1.26M$5.73M$7.88M$7.69M$7.70M
Revenue growth (YoY)——+7.4%+445.5%+354.7%+37.5%-2.4%+0.1%
Cost of revenue$302000.00$26.00M$40.36M$75.66M$73.12M$61.54M$2.18M$1.49M
Gross profit$-302000.00$215000.00$-40.13M$-74.39M$-67.39M$-53.67M$7.69M$6.20M
Gross margin—100.0%-17370.6%-5904.4%-1176.4%-681.4%100.0%80.6%
R&D$9.42M$26.00M$40.36M$75.66M$73.12M$61.54M$57.47M$28.53M
SG&A$2.21M$5.18M$9.06M$18.39M$22.93M$22.53M$18.46M$13.79M
Operating income$-11.63M$-30.97M$-49.18M$-92.79M$-90.32M$-76.20M$-73.05M$-34.63M
Operating margin—-14404.2%-21290.9%-7364.1%-1576.6%-967.4%-949.9%-450.1%
EBITDA$-11.33M$-30.63M$-48.57M$-91.59M$-88.66M$-74.34M$-66.45M$-33.14M
EBITDA margin—-14248.4%-21026.4%-7269.4%-1547.5%-943.9%-864.2%-430.7%
EBIT$-11.63M$-30.97M$-49.18M$-92.79M$-90.32M$-76.20M$-68.24M$-34.63M
Interest expense$0.00$0.00$0.00$5.80M$2.22M———
Income tax————————
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-11.59M$-30.49M$-60.73M$-98.59M$-88.10M$-69.20M$-63.12M$-33.38M
Net income growth (YoY)—-163.1%-99.2%-62.3%+10.6%+21.5%+8.8%+47.1%
Profit margin—-14180.0%-26289.2%-7824.7%-1537.8%-878.6%-820.8%-433.7%